Clinical Trial

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Study acronym: ITAD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-12-19; most recent amendment 2025-09-29.
Status change: Recruiting → Active, Not Recruiting 2021-12-15
Status change: Not Yet Recruiting → Recruiting 2019-09-02
Trial Details
NCT Number NCT03782636
Lead Sponsor University of Oxford
Collaborators: Oxford Clinical Trials Research Unit (OCTRU), Centre for Statistics in Medicine, Oxford, Juvenile Diabetes Research Foundation, Wellcome Trust
Conditions Type1 Diabetes
Enrollment 41 participants
Start Date 2019-01-28
Primary Completion 2023-02-16 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-10-03